Pieris Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference

May 20, 2021 8:00 AM

BOSTON, MA / ACCESSWIRE / May 20, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced today that management is scheduled to participate in a fireside chat at the Jefferies 2021 Virtual Healthcare Conference on Friday, June 4, 2021 at 1:00 PM EDT. A...

Read more

Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever

May 20, 2021 7:05 AM

New formulation delivers up to 2,708% more CBD into bloodstream* Human clinical hypertension study HYPER-H21-1 also progressing KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce successful test results of two new "DehydraTECH™ 2.0" cannabidiol...

Read more

Pressure BioSciences, Inc. Reports Resurgent Growth with Strong First Quarter 2021 Financial Results and Provides Business Update

May 19, 2021 9:30 AM

Significant Growth Reported in Total Revenue (121%), Instrument Sales (235%), and Consumable Products (81%); Definitive Progress Continued in the BaroFold and UST Platforms; Closure Expected Soon on Agrochemical Supplier Asset Acquisition Investor Conference Call Scheduled for Wednesday, May 19, 2021 at 4:30 p.m. EDT SOUTH EASTON, MA / ACCESSWIRE / May 19, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the...

Read more

EV Biologics Updates Shareholders on Name and Symbol Change

May 19, 2021 9:00 AM

CHEYENNE, WY / ACCESSWIRE / May 19, 2021 / EV Biologics Corp., OTC PINK:YECO, is taking this opportunity to update our shareholders and other investors concerning the status of our name change submission to the Financial Industry Regulatory Authority (FINRA). As some might be aware, such submissions can be a lengthy and complex process, requiring notarized documents. On April 12, 2019, the Company filed Articles of Continuance with the...

Read more

Applied UV and 3Sixty Biopharmaceuticals Sign Exclusive Distribution Agreement for Airocide(R) Air Purification Systems for the Continent of Africa

May 19, 2021 8:30 AM

$3.5 million minimum first year purchase commitment of Airocide® systems MOUNT VERNON, NY / ACCESSWIRE / May 19, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and...

Read more

HAVN Life Secures Production & Supply Agreement to Expand Retail Product Offerings

May 19, 2021 8:00 AM

Natural Health Products Will Be Manufactured and Packaged at the Company's New Facility VANCOUVER, BC / ACCESSWIRE / May 19, 2021 / HAVN Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "HAVN Life"), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce a production and supply agreement...

Read more

Nascent Biotech and BioRay Pharmaceutical Announce $5,000,000 Exclusive License Agreement for Development and Commercialization of Nascent's Pritumumab

May 19, 2021 8:00 AM

TAIZHOU, ZHEJIANG, CHINA & SAN DIEGO, CA / ACCESSWIRE / May 19, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) and BioRay Pharmaceutical Ltd., today announced that Nascent Biotech ("Nascent" or the "Company") has entered into a license agreement (the "Agreement") with BioRay Pharmaceutical Co Ltd ("BioRay"), thereby granting to BioRay exclusive rights to commercialize Nascent's monoclonal antibody,...

Read more

Viewpoint Molecular Targeting(TM) Bolsters its Board of Directors with Appointment of Charles Link, M.D., FACP

May 18, 2021 10:00 AM

Medical Oncologist and Industry Innovator With Over 20 Years of Experience in Discovery, Development and Commercialization of Oncology Therapies CORALVILLE, IA / ACCESSWIRE / May 18, 2021 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced...

Read more

With Sales Up Over 120%, Pressure BioSciences to Host Q1 2021 Financial Results and Business Update on Wednesday, May 19, 2021

May 18, 2021 9:10 AM

Q1 Financial Results Strongest Since Q4 2018; Q2 Revenue Already Exceeds Q2 2020. Purchase of Accretive, Eco-Friendly Agrochemical Supplier Nearing Close. SOUTH EASTON, MA / ACCESSWIRE / May 18, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its First Quarter 2021 financial results and provide a business update. Anyone...

Read more

Experion Holdings AGM to be Hosted Virtually May 26, 2021

May 18, 2021 8:45 AM

VANCOUVER, BC / ACCESSWIRE / May 18, 2021 / Experion Holdings Ltd. (the "Company" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) is pleased to announce the annual and special virtual-only meeting (the "Meeting") of holders of common shares (the "Shares") of Experion will be held on Wednesday, May 26, 2021 at 11:00 a.m. (Pacific time). Due to concerns regarding the coronavirus outbreak and to...

Read more

Oncology Pharma, Inc. Is Pursuing the Development of Its Small Molecule Drug for the Treatment of Colon Cancer

May 18, 2021 8:00 AM

SAN FRANCISCO, CA / ACCESSWIRE / May 18, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is pursuing, through its licensing arrangements, the development of a small molecule drug ("SMD") for the treatment of colon cancer. SMD is defined as any organic compound that enters cells easily because it has low molecular weight (< 900 daltons). Once inside the cells, it can affect other...

Read more

Thermic Science Sends First North American Shipment of Thermic Infrared Heating Paint for N.A. Certification, Retail Consumer Sales, and Further R&D for Its Advanced Thermic Technology to Successfully Disrupt the Immense and Disadvantaged North American Power and Heating Industry

May 17, 2021 1:30 PM

NASHVILLE, TN / ACCESSWIRE / May 17, 2021 / Thermic Science International Corporation, formerly known as Omnicanna Health Solutions, Inc. aka ENDOCAN CORP. (WKN:A1W61J)(ISIN:US29271J1097)(OTC PINK:ENDO), is pleased to announce that the first batch of the North American Shipments of the Thermic Infrared Heating Paint has been sent for N.A. Certification, Retail Consumer Sales, and Further R&D. The Advanced Thermic Technology has...

Read more

Applied UV Reports First Quarter 2021 Results

May 17, 2021 7:00 AM

MOUNT VERNON, NY / ACCESSWIRE / May 17, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced first quarter results for 2021. Q Saeed, Chief...

Read more

Pieris Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 17, 2021 7:00 AM

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON MONDAY, MAY 17, 2021 AT 8:00 AM EDT PRS-060/AZD1402 dosed to first patient in phase 2a study Cinrebafusp alfa (PRS-343) phase 2 study expected to begin this summer Announced license and collaboration agreement with Boston Pharmaceuticals for PRS-342, a preclinical 4-1BB/GPC3 immuno-oncology bispecific; Pieris to receive $10 million upfront payment and is eligible to receive up to...

Read more

Edesa Biotech Reports Fiscal 2nd Quarter 2021 Results

May 14, 2021 8:00 AM

TORONTO, ON / ACCESSWIRE / May 14, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and six months ended March 31, 2021 and provided an update on its business. The company reported that it has enrolled more than 285 patients in an ongoing Phase 2/3 clinical study of its investigational drug, EB05, as a...

Read more

Dyadic Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress

May 13, 2021 4:00 PM

Advancing Dyadic's proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial Goal of validating that C1 produced proteins are safe in humans and to accelerate adoption and use of C1 technology platform for the development and manufacture of vaccines and therapeuticsGoal of bringing larger quantities of lower cost COVID-19 vaccines that can be used as a prime and booster to existing vaccinesEngaged...

Read more

Pressure BioSciences Awarded Three Additional Patents for Revolutionary Ultra Shear Technology Platform

May 13, 2021 10:10 AM

Unique Commercial-Scale Capabilities for Highest-Quality Nanoemulsions of Oils in Water Enabled by PBI's UST Platform, Addressing Multiple Billion Dollar Opportunities in Diverse Markets Worldwide SOUTH EASTON, MA / ACCESSWIRE / May 13, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform...

Read more

Helix BioPharma Corp. Announces Closing of First Tranche of Institutional Investment for Gross Proceeds of CAD$3.5 million

May 13, 2021 9:00 AM

RICHMOND HILL, ON / ACCESSWIRE / May 13, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has closed the first tranche of the previously announced private placement pursuant to the convertible security funding agreement (the "Agreement") with Lind Global Macro Fund,...

Read more

Oncology Pharma, Inc. Has Submitted Its Initial Application to List the Company on the Capital Markets Tier of the NASDAQ Exchange

May 12, 2021 10:10 PM

SAN FRANCISCO, CA / ACCESSWIRE / May 12, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") has submitted its initial application to the NASDAQ to begin the process of moving the listing from the Pink Sheets to the Capital Markets Tier of the NASDAQ Exchange. The Company, its Board, advisors and management team are going to devote resources to accomplish this as swiftly as possible. We are...

Read more

Apollo Endosurgery to Present at Sidoti Conference May 20

May 12, 2021 4:05 PM

AUSTIN, TX / ACCESSWIRE / May 12, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures today announced that it will participate in the Sidoti & Company Virtual Microcap Conference on May 20, 2021. Management will present an overview presentation on Thursday, May 20, at 10:00 am Eastern Standard Time. A live and archive webcast link...

Read more